[非小细胞肺癌中微小RNA与表皮生长因子受体酪氨酸激酶抑制剂继发耐药的研究进展]
[Advance in microRNAs and EGFR-TKIs secondary resistance research in non-small cell lung cancer].
作者信息
Duan Xiaoyang, Shi Jian
机构信息
Graduate Student of Hebei Medical University, Shijiazhuang 050000, China.
Department of Medical Oncology, Hebei Province Cancer Hospital, Shijiazhuang 050000, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2014 Dec;17(12):860-4. doi: 10.3779/j.issn.1009-3419.2014.12.07.
Abstract
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed briefly advance in miRNAs and EGFR-TKIs secondary resistance research in NSCLC.
摘要
近年来，在非小细胞肺癌（NSCLC）的靶向治疗中，尤其是在表皮生长因子受体（EGFR）突变的患者中，EGFR酪氨酸激酶抑制剂（TKI）越来越多地进入临床治疗，但EGFR-TKI耐药不仅影响药物敏感性，甚至出现疾病进展，成为其疗效的主要瓶颈。微小RNA（miRNAs）是一种参与转录水平基因表达调控的非编码RNA。最近的研究发现，miRNAs参与了EGFR-TKIs耐药，影响肿瘤细胞对治疗的敏感性。本文简要综述了NSCLC中miRNAs与EGFR-TKIs继发性耐药研究的进展。
相似文献
1
[Advance in microRNAs and EGFR-TKIs secondary resistance research in non-small cell lung cancer].[非小细胞肺癌中微小RNA与表皮生长因子受体酪氨酸激酶抑制剂继发耐药的研究进展]
Zhongguo Fei Ai Za Zhi. 2014 Dec;17(12):860-4. doi: 10.3779/j.issn.1009-3419.2014.12.07.
2
[Advanced Research on MicroRNAs and EGFR-TKIs Secondary Resistance].[微小RNA与表皮生长因子受体酪氨酸激酶抑制剂继发性耐药的前沿研究]
Zhongguo Fei Ai Za Zhi. 2015 Dec;18(12):758-63. doi: 10.3779/j.issn.1009-3419.2015.12.08.
3
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.非小细胞肺癌中与表皮生长因子受体酪氨酸激酶抑制剂耐药相关的长链非编码RNA的转录组分析
Biomed Pharmacother. 2017 Mar;87:20-26. doi: 10.1016/j.biopha.2016.12.079. Epub 2016 Dec 29.
4
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
5
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.胰岛素样生长因子1受体（IGF-1R）的表达预示着携带激活型表皮生长因子受体（EGFR）突变的非小细胞肺癌患者对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂反应不佳。
Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.
6
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.表皮生长因子受体突变的非小细胞肺癌中的下一代表皮生长因子受体酪氨酸激酶抑制剂
Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8.
7
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
8
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.中国非小细胞肺癌患者中Bim缺失多态性的临床特征及其与酪氨酸激酶抑制剂耐药性的关系。
Cancer. 2014 Aug 1;120(15):2299-307. doi: 10.1002/cncr.28725. Epub 2014 Apr 15.
9
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.miR-21 过表达与非小细胞肺癌中 EGFR-TKI 的获得性耐药相关。
Lung Cancer. 2014 Feb;83(2):146-53. doi: 10.1016/j.lungcan.2013.11.003. Epub 2013 Nov 13.
10
Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.上皮-间质转化在IGF1R诱导的晚期非小细胞肺癌对EGFR-TKIs耐药中的作用
Oncotarget. 2015 Dec 29;6(42):44332-45. doi: 10.18632/oncotarget.6293.
引用本文的文献
1
The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.miR-128在癌症发生、预防、耐药性及免疫治疗中的作用。
Front Oncol. 2023 Jan 19;12:1067974. doi: 10.3389/fonc.2022.1067974. eCollection 2022.
2
MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and Prognosis.微小RNA-873-5p：一种用于癌症诊断和预后的潜在分子标志物。
Front Oncol. 2021 Oct 5;11:743701. doi: 10.3389/fonc.2021.743701. eCollection 2021.
3
MicroRNA‑128‑b regulates epidermal growth factor receptor expression in non‑small cell lung cancer.MicroRNA-128-b 调控非小细胞肺癌中表皮生长因子受体的表达。
Mol Med Rep. 2019 Dec;20(6):4803-4810. doi: 10.3892/mmr.2019.10731. Epub 2019 Oct 8.
4
MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.miR-873 抑制通过靶向神经胶质瘤相关癌基因同源物 1 增强非小细胞肺癌细胞对吉非替尼的耐药性。
Thorac Cancer. 2018 Oct;9(10):1262-1270. doi: 10.1111/1759-7714.12830. Epub 2018 Aug 20.
5
Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.表皮生长因子受体基因的突变及其对吉非替尼治疗晚期非小细胞肺癌疗效的影响。
Int J Clin Exp Med. 2015 Apr 15;8(4):5397-405. eCollection 2015.
本文引用的文献
1
microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.微小RNA-128通过直接靶向血管内皮生长因子-C，在人类非小细胞肺癌的肿瘤发生、血管生成和淋巴管生成中发挥关键作用。
Eur J Cancer. 2014 Sep;50(13):2336-50. doi: 10.1016/j.ejca.2014.06.005. Epub 2014 Jul 4.
2
CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.在具有表皮生长因子受体突变的肺癌中，CRKL扩增作为对激酶抑制剂获得性耐药的一种机制较为罕见。
Lung Cancer. 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Epub 2014 Jun 2.
3
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.miR-138-5p 通过负向调控 G 蛋白偶联受体 124 逆转非小细胞肺癌细胞对吉非替尼的耐药性。
Biochem Biophys Res Commun. 2014 Mar 28;446(1):179-86. doi: 10.1016/j.bbrc.2014.02.073. Epub 2014 Feb 28.
4
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.胰岛素样生长因子1受体在具有野生型表皮生长因子受体的肺癌细胞中导致对厄洛替尼产生获得性耐药。
Int J Cancer. 2014 Aug 15;135(4):1002-6. doi: 10.1002/ijc.28737. Epub 2014 Feb 4.
5
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.miR-21 过表达与非小细胞肺癌中 EGFR-TKI 的获得性耐药相关。
Lung Cancer. 2014 Feb;83(2):146-53. doi: 10.1016/j.lungcan.2013.11.003. Epub 2013 Nov 13.
6
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.MiR-134/487b/655簇通过靶向肺癌腺癌细胞中的MAGI2来调节转化生长因子-β诱导的上皮-间质转化和对吉非替尼的耐药性。
Mol Cancer Ther. 2014 Feb;13(2):444-53. doi: 10.1158/1535-7163.MCT-13-0448. Epub 2013 Nov 20.
7
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.抑制 Hedgehog 信号通过调节 EMT 调节 miRNA 使 NSCLC 细胞对标准治疗敏感。
J Hematol Oncol. 2013 Oct 7;6(1):77. doi: 10.1186/1756-8722-6-77.
8
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.EGFR 突变 NSCLC 细胞中获得性耐药的一种新型机制：EGFR-TKIs 治疗过程中 7 号染色体 EGFR 扩增丢失。
Lung Cancer. 2014 Jan;83(1):44-50. doi: 10.1016/j.lungcan.2013.10.003. Epub 2013 Oct 16.
9
Cancer statistics for African Americans, 2013.美国非洲裔癌症统计数据，2013 年。
CA Cancer J Clin. 2013 May;63(3):151-66. doi: 10.3322/caac.21173. Epub 2013 Feb 5.
10
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.微小RNA-214通过PTEN/AKT途径调节表皮生长因子受体（EGFR）突变细胞系对吉非替尼的获得性耐药。
Asian Pac J Cancer Prev. 2012;13(1):255-60. doi: 10.7314/apjcp.2012.13.1.255.
Zotero 插件